"10.1371_journal.pone.0022605","plos one","2011-07-27T00:00:00Z","Jianfeng Zhang; E Bart Tarbet; Tsungwei Feng; Zhongkai Shi; Kent R Van Kampen; De-chu C Tang","Vaxin, Inc., Birmingham, Alabama, United States of America; Institute for Antiviral Research, Utah State University, Logan, Utah, United States of America","Conceived and designed the experiments: DCT EBT. Performed the experiments: JZ EBT TF ZS KVK DCT. Analyzed the data: JZ EBT KVK DCT. Contributed reagents/materials/analysis tools: JZ EBT DCT. Wrote the paper: DCT.","A provisional patent application on the drug-vaccine duo technology was filed by Vaxin scientists in March 2011.  JZ, TF, ZS, KVK, and DCT are employees at Vaxin and are involved in product development. However, this does not alter the authors adherence to all the PLoS ONE policies on sharing data and materials. EBT at USU has no competing interests and was authorized by the NIH to validate Vaxins anti-dogmatic results through an NIAID Non-Clinical Evaluation Agreement.","2011","07","Jianfeng Zhang","JZ",6,FALSE,2,6,4,1,TRUE,TRUE,FALSE,0,NA,FALSE
